Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Transvaginal intraovarian loteprednol etabonate injection for premature ovarian insufficiency
ChiCTR2600130235Phase 4Not yet recruiting
- Sponsor
- The University of Hong Kong-Shenzhen Hospital
- Start
- Aug 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of loteprednol etabonate in ovarian hypofunction (POI), sponsored by The University of Hong Kong-Shenzhen Hospital. Primary endpoint: Number of antral follicles and mature follicles (AFCs). Planned start Aug 2026; status: not yet recruiting.
02
Drugs
loteprednol etabonate
03
Conditions
ovarian hypofunction (POI)
Beyond the preview
Go deeper on ChiCTR2600130235.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600130235.